These therapies focus on overcoming immune evasion mechanisms in the TME to reinvigorate T-cell-mediated antitumor immunity.1 The success of ICB is often linked to the presence of an “inflamed” TME, which is marked by a significant infiltration of tumor-specific CD8+ T cells required to trigger an effective cytotoxic immune response. Here, CD8A is linked to neoplasm.